Searching for Solutions, Father of Medically Fragile Daughter Creates Hemp-based Topical Cannanumb®

Tuesday, October 1, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Cannanumb® by Hempagenix™ is an FDA-registered, over-the-counter (OTC) pain product for those seeking alternatives to opioids and other pain medications.

WESTON, Fla., Oct. 1, 2019 /PRNewswire-PRWeb/ -- Seth Hyman is the father of a 13-year-old

daughter, who suffers from a severe genetic disorder and daily seizures. Having tried more than three dozen different drugs, along with numerous holistic and homeopathic treatments with no results, he had few options left to help her.

He dedicated his life to finding a solution, and while researching different treatment options, he became aware of the potential benefits of hemp and plant-based products. Not only to help his daughter, but also the millions of individuals who could benefit from the use of these treatments for a variety of conditions.

A long-time advocate for the hemp industry and the benefits of plant-based medicines, Hyman founded Hempagenix™ and created its signature product, Cannanumb®. Unlike many other products currently on the market, Cannanumb® does not contain CBD; ingredients including organic cannabis sativa hemp seed oil and maximum strength lidocaine, along with other pain-fighting ingredients, work together to deeply penetrate the skin's dermal layer, providing relief to aggravated nerves.

Having seen the difference plant-based products have made in Rebecca's life, Hyman is more determined than ever to provide innovative hemp-based health and wellness solutions to those who need them. To learn more about the Hyman's story, visit http://www.hempagenix.com.

Note to editors: Seth Hyman is available for interviews to discuss how hemp and plant-based medicines have impacted his daughter Rebecca's life, as well as the lives of countless others. Contact media@hempagenix.com with any inquiries.

 

SOURCE Hempagenix



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store